Clinical trials: Leukemia, Acute
Acute Leukemia, Chronic Myeloid Leukemia
Allo-HSCT With Alternative Donor in Treatment of Hematologic Malignancy
The purpose of this study is to compare the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) from matched sibling donor (MSD),matched unrelated donor (MUD) and haploidentical related donors(HRD) in the…
- Conditions
- Acute Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT02487069
- Testing
- HSCT from MSD, HSCT from MUD, HSCT from HRD
- Where
- China
- Volunteers
- 876 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Acute Myeloid Leukemia (AML)
Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR
This open label, multicenter phase II/III study with multiple randomization phases at differents stages of AML treatment (induction, consolidation and HSCT where applicable) is designed to improve OS in younger (18 to 60…
- Trial name
- BIG-1 (NCT02416388)
- Testing
- Idarubicin, Daunorubicin, HD Cytarabine
- Where
- 56 sites in France
- Volunteers
- 3,100 people
- Sponsor
- University Hospital, Angers
B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL)…
- Conditions
- B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma
- Trial name
- NCT06395103
- Testing
- Zilovertamab vedotin
- Where
- 71 sites in United States, Australia and 21 more
- Volunteers
- 90 people
- Sponsor
- Merck Sharp & Dohme LLC
Leukemia
Mitomycin and Mitoxantrone in Treating Patients With Acute Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Some cancers become resistant to chemotherapy drugs.
- Trial name
- NCT00003003
- Testing
- sargramostim, mitomycin C, mitoxantrone hydrochloride
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Acute Myeloid Leukemia
Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia
This phase Ib/II trial tests the safety of tagraxofusp when given with or without azacitidine in patients with acute myeloid leukemia in remission with measurable residual disease who will undergo allogeneic hematopoietic cell…
- Trial name
- NCT05720988
- Testing
- Azacitidine, Tagraxofusp-erzs
- Where
- 2 sites in United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Acute Myeloid Leukemia
Phase I Clinical Trial of RC1012 Injection in Patients With r/r AML
To evaluate the safety and tolerability of RC1012 infusion in patients with relapsed or refractory Acute Myelocytic Leukemia (r/r AML).
- Trial name
- NCT05471323
- Testing
- RC1012 injection (allo-DNT cells)
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Guangdong Ruishun Biotech Co., Ltd
Leukemia
Donor Peripheral Stem Cell Transplant in Treating Patients With Relapsed Acute Myeloid Leukemia
RATIONALE: Giving chemotherapy before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells.
- Trial name
- NCT00274846
- Testing
- aldesleukin, therapeutic allogeneic lymphocytes, cyclophosphamide
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy
Mitoxantrone Hydrochloride Liposome Injection, Cytarabine Combined With Venetoclax in the Treatment of R/R AML
The goal of this study is to evaluate the efficacy and safety of a combination regimen of mitoxantrone hydrochloride liposome injection, cytarabine and venetoclax (MAV) in the treatment of relapsed or refractory (R/R) AML.
- Trial name
- NCT06434662
- Testing
- mitoxantrone hydrochloride liposome, Cytarabine, Venetoclax
- Where
- China
- Volunteers
- 34 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Breast Cancer, Leukemia
Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Breast Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00237627
- Testing
- PS-341, Doxil, Velcade
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Neoplasms, Hematologic Neoplasms
CD155 Expression in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy. It is the most common form of acute leukemia among adults. In the United States, an estimated 19,940 people will be diagnosed with AML in 2020.
- Conditions
- Neoplasms, Hematologic Neoplasms, Leukemia, Leukemia, Myeloid
- Trial name
- NCT06369662
- Testing
- Flow cytometric immunophenotyping, Complete blood count, Bone marrow aspiration
- Where
- Egypt
- Volunteers
- 93 people
- Sponsor
- Assiut University
Drug/Agent Toxicity by Tissue/Organ, Leukemia
Amifostine and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003268
- Testing
- amifostine trihydrate, cytarabine, idarubicin
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
AML, Adult
A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)
This is a Phase Ib/II, open-label, multi-center study evaluating the safety, tolerability, efficacy and PK of APG-2575 in combination with Azacitidine in the patients with AML/MPAL or MDS/CMML.
- Trial name
- NCT04964518
- Testing
- APG 2575 ramp up arm
- Where
- 9 sites in United States, Australia
- Volunteers
- 24 people
- Sponsor
- Ascentage Pharma Group Inc.
Leukemia, Myelodysplastic Syndromes
6-Hydroxymethylacylfulvene in Treating Patients With Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Blastic Phase Chronic Myelogenous Leukemia
Phase I trial to study the effectiveness of 6-hydroxymethylacylfulvene in treating patients who have refractory myelodysplastic syndrome, acute myeloid leukemia, acute lymphocytic leukemia, or blastic phase chronic myelogenous…
- Trial name
- NCT00003997
- Testing
- irofulven
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia
Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders
This phase I trial is studying the side effects and best dose of veliparib when given together with topotecan hydrochloride with or without carboplatin in treating patients with relapsed or refractory acute leukemia, high-risk…
- Conditions
- Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia, Adult Acute Monocytic Leukemia, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
- Trial name
- NCT00588991
- Testing
- Carboplatin, Laboratory Biomarker Analysis, Topotecan Hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is among the most common hematologic malignancies in adults and accounts for approximately 10,000 deaths in the United States every year. AML is commonly diagnosed in sixth or seventh decades of life.
- Conditions
- Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia
- Trial name
- NCT03226418
- Testing
- Cytarabine, Decitabine, Idarubicin
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Nebraska
Acute Myeloid Leukemia, Maintenance Therapy
Chidamide in HR-AML
Acute myeloid leukemia (AML) patients with fusion gene-positive including core binding factor (CBF), mixed-lineage leukemia (MLL) gene rearrangement have a high incidence of relapse if they have continuously positive measurable…
- Trial name
- NCT07822789
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Guangdong Second Provincial General Hospital
B ALL, Allogenetic Hematopoietic Stem Cell Transplantation
CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT
This prospective, open-label randomized controlled trial compares CD19 CAR-T therapy with chemotherapy plus donor lymphocyte infusion (DLI) in 70 patients with Ph-negative B-cell acute lymphoblastic leukemia (B-ALL) who exhibited…
- Conditions
- B ALL, Allogenetic Hematopoietic Stem Cell Transplantation, MRD-positive
- Trial name
- NCT07441291
- Testing
- CAR-T, DLI
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Peking University People's Hospital
Acute Leukemia
Emotion and Symptom-Focused Engagement Trial for Individuals With Acute Leukemia
The purpose of this study is to find out whether a novel manualized intervention, called Emotion and Symptom-focused Engagement (EASE), that combines psychological support with symptom screening plus triggered referral to early…
- Trial name
- EASE (NCT04224974)
- Testing
- Usual Care, EASE-psy
- Where
- 6 sites in Canada
- Volunteers
- 266 people
- Sponsor
- Canadian Cancer Trials Group
Pediatric Acute Leukemia
A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and Relapsed /Refractory Pediatric Acute Leukemia Patients
The goal of Phase 1a of this clinical research study is to find the highest tolerable dose of revumenib that can be given in combination with cytarabine, daunorubicin, and gemtuzumab ozogamicin to patients who have acute…
- Trial name
- NCT07052994
- Testing
- Revumenib, Cytrabine, Daunorubicin
- Sponsor
- M.D. Anderson Cancer Center
AML
NKG2D CAR-NK & r/rAML
This trial will explore the maximum tolerated dose（MTD）of NKG2D CAR-NK cells in the treatment of relapsed or/and refractory AML in a dose-escalation manner, and observe the clinical safety and efficacy.
- Trial name
- NCT05734898
- Testing
- NKG2D CAR-NK
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Zhejiang University